ARCALIS, Inc., (Headquarters: Minamisoma City, Fukushima Prefecture; President and CEO: Satoshi Takamatsu, hereinafter “ARCALIS”) is pleased to announce the signing of a collaboration agreement with the National Cancer Center Japan (Location: Chuo-ku, Tokyo; President: Hitoshi Nakagama, hereinafter “National Cancer Center”) for the research, development, and manufacturing of mRNA pharmaceuticals.

Under this agreement, ARCALIS will support the social implementation of basic seeds related to mRNA drug discovery, which involves the NCC-CPOT (Center for Promotion of Translational Research) of the National Cancer Center. Additionally, ARCALIS will cooperate from a CDMO (Contract Development and Manufacturing Organization) standpoint in promoting clinical trials and clinical studies of mRNA pharmaceuticals, primarily conducted by NCC-EPOC (Exploratory Oncology Research & Clinical Trial Center) of the National Cancer Center.

Regarding this partnership, President and CEO, Satoshi Takamatsu of ARCALIS commented, “We are honored and delighted to have signed this agreement with the National Cancer Center. This collaboration strengthens our ties with the National Cancer Center and enables ARCALIS to play a crucial role in the research, development, and manufacturing of mRNA pharmaceuticals. We will continue to prioritize the health and safety of patients, aiming to contribute to the advancement of Japan’s medical industry and the overall health and welfare of the international community through the production of high-quality and safe mRNA.”

Here is the news page of ARCALIS  https://corp.arcalis.co.jp/en/news/20240730nationalcancercenterjapanpartnershipen/